FyMed Inc

FyMed, Inc. today announced results from comparative in-vivo studies of FY101C, its lead NSAID candidate, which demonstrated significant superiority to conventional NSAIDs in terms of efficacy and safety in the management of pain and inflammation.

FyMed, Inc., a biopharmaceutical company today announced strategic and operational expansion plans following the successful completion of major preclinical drug studies utilizing proprietary companion diagnostics and prognostic technologies.